evidence for benefit is unclear; 4) these preparations may have unforeseeable adverse effects; 5) the availability of high quality preparations is unclear; and 6) resource impact (ie, costs) is unknown. Release and implementation of the recommendations. See online supplementary file S2, on the Arthritis & Rheumatology web site at http://onlinelibrary Cost implications and conflicts of interest. Cost implications are outside the scope of these recommendations. None of the panel members disclosed any conflict of interest associated with the development of these recommendations. Discussion See online supplementary file S3 ( http://online We recognize that our recommendations are only partially supported by evidence, and that they do not cover all aspects important for the management of PMR. The group therefore unanimously agreed that the research agenda (containing the evidence gaps related to PMR management) is an important result of this project (Box 2). Due to our rigorous SLR